These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 3015143)

  • 61. Substrate specificity and phosphorylation of antiviral and anticancer nucleoside analogues by human deoxyribonucleoside kinases and ribonucleoside kinases.
    Van Rompay AR; Johansson M; Karlsson A
    Pharmacol Ther; 2003 Nov; 100(2):119-39. PubMed ID: 14609716
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Antiretrovirus activity of a novel class of acyclic pyrimidine nucleoside phosphonates.
    Balzarini J; Pannecouque C; De Clercq E; Aquaro S; Perno CF; Egberink H; Holý A
    Antimicrob Agents Chemother; 2002 Jul; 46(7):2185-93. PubMed ID: 12069973
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Metabolism, mitochondrial uptake and toxicity of 2', 3'-dideoxycytidine.
    Rossi L; Serafini S; Schiavano GF; Casabianca A; Vallanti G; Chiarantini L; Magnani M
    Biochem J; 1999 Dec; 344 Pt 3(Pt 3):915-20. PubMed ID: 10585881
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Intracellular phosphorylation of zidovudine (ZDV) and other nucleoside reverse transcriptase inhibitors (RTI) used for human immunodeficiency virus (HIV) infection.
    Peter K; Gambertoglio JG
    Pharm Res; 1998 Jun; 15(6):819-25. PubMed ID: 9647345
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Zalcitabine population pharmacokinetics: application of radioimmunoassay.
    Adams JM; Shelton MJ; Hewitt RG; DeRemer M; DiFrancesco R; Grasela TH; Morse GD
    Antimicrob Agents Chemother; 1998 Feb; 42(2):409-13. PubMed ID: 9527795
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Zalcitabine. An update of its pharmacodynamic and pharmacokinetic properties and clinical efficacy in the management of HIV infection.
    Adkins JC; Peters DH; Faulds D
    Drugs; 1997 Jun; 53(6):1054-80. PubMed ID: 9179531
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Potent activity of 2'-beta-fluoro-2',3'-dideoxyadenosine against human immunodeficiency virus type 1 infection in hu-PBL-SCID mice.
    Ruxrungtham K; Boone E; Ford H; Driscoll JS; Davey RT; Lane HC
    Antimicrob Agents Chemother; 1996 Oct; 40(10):2369-74. PubMed ID: 8891146
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Efficiency of nanoparticles as a carrier system for antiviral agents in human immunodeficiency virus-infected human monocytes/macrophages in vitro.
    Bender AR; von Briesen H; Kreuter J; Duncan IB; Rübsamen-Waigmann H
    Antimicrob Agents Chemother; 1996 Jun; 40(6):1467-71. PubMed ID: 8726020
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Comparative pharmacokinetics of antiviral nucleoside analogues.
    Morse GD; Shelton MJ; O'Donnell AM
    Clin Pharmacokinet; 1993 Feb; 24(2):101-23. PubMed ID: 8453821
    [TBL] [Abstract][Full Text] [Related]  

  • 70. In vitro activities of nucleoside analog antiviral agents against salmonellae.
    Sperber SJ; Feibusch EL; Damiani A; Weinstein MP
    Antimicrob Agents Chemother; 1993 Jan; 37(1):106-10. PubMed ID: 8431005
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Differential phosphorylation of azidothymidine, dideoxycytidine, and dideoxyinosine in resting and activated peripheral blood mononuclear cells.
    Gao WY; Shirasaka T; Johns DG; Broder S; Mitsuya H
    J Clin Invest; 1993 May; 91(5):2326-33. PubMed ID: 8387546
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Intracellular metabolism of (-)- and (+)-cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine in HepG2 derivative 2.2.15 (subclone P5A) cells.
    Paff MT; Averett DR; Prus KL; Miller WH; Nelson DJ
    Antimicrob Agents Chemother; 1994 Jun; 38(6):1230-8. PubMed ID: 8092819
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Metabolism and mechanism of antiretroviral action of purine and pyrimidine derivatives.
    Balzarini J
    Pharm World Sci; 1994 Apr; 16(2):113-26. PubMed ID: 8032337
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Clinical pharmacology of zidovudine and other 2',3'-dideoxynucleoside analogues.
    Kamali F
    Clin Investig; 1993 May; 71(5):392-405. PubMed ID: 7685214
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Zalcitabine. Clinical pharmacokinetics and efficacy.
    Devineni D; Gallo JM
    Clin Pharmacokinet; 1995 May; 28(5):351-60. PubMed ID: 7614775
    [TBL] [Abstract][Full Text] [Related]  

  • 76. 2',3'-Dideoxycytidine metabolism in a new drug-resistant cell line.
    Magnani M; Brandi G; Casabianca A; Fraternale A; Schiavano GF; Rossi L; Chiarantini L
    Biochem J; 1995 Nov; 312 ( Pt 1)(Pt 1):115-23. PubMed ID: 7492300
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Broad spectrum antiretroviral activity of 2',3'-dideoxynucleosides.
    Dahlberg JE; Mitsuya H; Blam SB; Broder S; Aaronson SA
    Proc Natl Acad Sci U S A; 1987 Apr; 84(8):2469-73. PubMed ID: 3470806
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Ribavirin antagonizes inhibitory effects of pyrimidine 2',3'-dideoxynucleosides but enhances inhibitory effects of purine 2',3'-dideoxynucleosides on replication of human immunodeficiency virus in vitro.
    Baba M; Pauwels R; Balzarini J; Herdewijn P; De Clercq E; Desmyter J
    Antimicrob Agents Chemother; 1987 Oct; 31(10):1613-7. PubMed ID: 3435108
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Pathogenesis of human immunodeficiency virus infection and prospects for control.
    Ho DD; Kaplan JC
    Yale J Biol Med; 1987; 60(6):589-600. PubMed ID: 3324508
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Treatment of human immunodeficiency virus infections.
    Hirsch MS; Kaplan JC
    Antimicrob Agents Chemother; 1987 Jun; 31(6):839-43. PubMed ID: 3304154
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.